



Appendix to report

Pharmaceutical treatment in forensic psychiatric care

Excluded studies

Benefits and risks, patients in forensic psychiatric care or equivalent

Population

Addis S, Sherwood D, Mace W, Mancuso SG, Koloth R, Castle DJ. A naturalistic study of pharmacological management of behavioural disturbance in psychosis. *Journal of Psychiatric Intensive Care*, 2012; 8 (2): 120-25.

Ahmadvand A, Sepehrmanesh Z, Sadat-Ghoreyshi F, Zahiroddin A. Therapeutic effect of methadone on improving symptoms of depression in prisoners with a history of substance misuse. *Iranian Journal of Psychiatry and Behavioral Sciences*, 2009; 3 (2): 29-32.

Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI. Benzodiazepine use and aggressive behaviour: A systematic review. *Australian and New Zealand Journal of Psychiatry*, 2014; 48 (12): 1096-114.

Allen M, Debanné M, Lazignac C, Adam E, Dickinson L, Damsa C. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. *The American journal of psychiatry*, 2011; 168 (4): 395-9.

Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. *Journal of Clinical Psychiatry*, 2015; 76 (5): 554-61.

Alphs L, Bossie C, Mao L, Lee E, Starr HL. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. *Early intervention in psychiatry*, 2015; 2525.

Anglin M, Conner B, Annon J, Longshore D. Longitudinal effects of LAAM and methadone maintenance on heroin addict behavior. *The journal of behavioral health services & research*, 2009; 36 (2): 267-82.

Arango C, Bombín I, González-Salvador T, García-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. *European psychiatry : the journal of the Association of European Psychiatrists*, 2006; 21 (1): 34-40.

Arango C, Bombin I, Gonzalez-Salvador T, Garcia-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. *European Psychiatry: the Journal of the Association of European Psychiatrists*, 2006; 21 (1): 34-40.

Barratt ES, Kent TA, Bryant SG, Felthous AR. A controlled trial of phenytoin in impulsive aggression. *Journal of Clinical Psychopharmacology*, 1991; 11 (6): 388-9.

Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. *Journal of Clinical Psychopharmacology*, 1997; 17 (5): 341-9.

Barrett B, Waheed W, Farrelly S, Birchwood M, Dunn G, Flach C, et al. Randomised controlled trial of joint crisis plans to reduce compulsory treatment for people with psychosis: economic outcomes (Provisional abstract). *Plos One*, 2013; 8 (11): 8 (11).

Beer MD, Khan AA, Ratnajothy K. The effect of clozapine on adverse incidents in a low-secure challenging behaviour unit. *Journal of Psychiatric Intensive Care*, 2006; 2 (2): 65-70.

Bennett DM, Bremner M, Gray C. The clinical use of plasma clozapine levels in a maximum security setting. *International Journal of Psychiatry in Clinical Practice*, 2008; 12 (3): 228-34.

Bleich A, Gelkopf M, Schmidt V, Hayward R, Bodner G, Adelson M. Correlates of benzodiazepine abuse in methadone maintenance treatment. A 1 year prospective study in an Israeli clinic. *Addiction*, 1999; 94 (10): 1533-40.

Bobes J, Fillat O, Arango C. Violence among schizophrenia out-patients compliant with medication: prevalence and associated factors. *Acta Psychiatrica Scandinavica*, 2009; 119 (3): 218-25.

Bouso J, Doblin R, Farré M, Alcázar M, Gómez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. *Journal of psychoactive drugs*, 2008; 40 (3): 225-36.

Brown C. The use of benzodiazepines in prison populations. *The Journal of clinical psychiatry*, 1978; 39 (3): 219-22.

Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. *Bulletin of the American Academy of Psychiatry & the Law*, 1995; 23 (4): 607-11.

Chang Z, Lichtenstein P, Langström N, Larsson H, Fazel S. Association between prescription of major psychotropic medications and violent reoffending after prison release. *JAMA - Journal of the American Medical Association*, 2016; 316 (17): 1798-807.

Chengappa KN, Vasile J, Levine J, Ulrich R, Baker R, Gopalani A, et al. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. *Schizophrenia Research*, 2002; 53 (1): 1-6.

Coviello D, Cornish J, Lynch K, Alterman A, O'Brien C. A randomized trial of oral naltrexone for treating opioid-dependent offenders. *The American journal on addictions*, 2010; 19 (5): 422-32.

Crispo AL, Lee KC, Kaftarian EL, Chen-Peng L. Evaluation of psychotropic medication adherence in a correctional facility. *Journal of Pharmacy Practice*, 2015; 28 (3): 324-25.

Dean A, London E, Sugar C, Kitchen C, Swanson A, Heinzerling K, et al. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. *Drug and alcohol dependence*, 2009; 105 (1): 48-55.

Dåderman AM, Lidberg L. Flunitrazepam (Rohypnol) abuse in combination with alcohol causes premeditated, grievous violence in male juvenile offenders. *Journal of the American Academy of Psychiatry and the Law*, 1999; 27 (1): 83-99.

Evans J, Platts H, Lightman S, Nutt D. Impulsiveness and the prolactin response to d-fenfluramine. *Psychopharmacology*, 2000; 149 (2): 147-52.

Fernandez-Quintana A, Vidal-Millares M, García-Mahía MC. A 10 year follow-up study of long acting injectable risperidone use in severe mental disorders. *European Neuropsychopharmacology*, 2016; 26S563-S64.

Fink BC, Steele VR, Maurer MJ, Fede SJ, Calhoun VD, Kiehl KA. Brain potentials predict substance abuse treatment completion in a prison sample. *Brain and Behavior*, 2016; 6 (8).

Franck J, Konstenius M, Jayaram-Lindstrom N, Philips B, Guterstam J. ADHD in drug addiction: A RCT on the feasibility of methylphenidate treatment in criminal amphetamine users. *International Journal of Neuropsychopharmacology*, 2012; 1541.

Frankle W, Shera D, Berger-Hershkowitz H, Evins A, Connolly C, Goff D, et al. Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories. *American Journal of Psychiatry*, 2001; 158 (2): 270-4.

Fuh L, Hays H, Brown N, Shirk MB. Characterization of drug overdoses in an Ohio incarcerated population. *Clinical Toxicology*, 2016; 54 (3): 266-70.

Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. *American Journal of Psychiatry*, 1985; 142 (1): 98-100.

Ginsberg Y, Hirvikoski T, Grann M, Lindefors N. Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate. *European Archives of Psychiatry and Clinical Neuroscience*, 2012; 262 (8): 705-24.

Ginsberg Y, Hirvikoski T, Grann M, Lindefors N. Osmotic-release oral system methylphenidate (OROS-MPH) treatment of adult prison inmates with ADHD: A randomised controlled trial with open-label extension. *European psychiatry*, 2013; 28.

Ginsberg Y, Langstrom N, Larsson H, Lindefors N. Long-Term Treatment Outcome in Adult Male Prisoners with Attention-Deficit/Hyperactivity Disorder: Three-Year Naturalistic Follow-Up of a 52-Week Methylphenidate Trial. *Journal of clinical psychopharmacology*, 2015; 35 (5): 535-43.

Ginsberg Y, Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: Randomised double-blind placebo-controlled trial with open-label extension. *British Journal of Psychiatry*, 2012; 200 (1): 68-73.

Gordon M, Kinlock T, Schwartz R, O'Grady K. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. *Addiction (abingdon, england)*, 2012; 103 (8): 1333-42.

Gowin JL, Green CE, Alcorn JL, Swann AC, Moeller FG, Lane SD. Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior. *Journal of Psychopharmacology*, 2012; 26 (7): 982-93.

Grann M, Ginsberg Y, Hirvikoski T, Lindefors N. Methylphenidate treatment of adult prison inmates with ADHD: A randomised double-blind placebo-controlled trial with open-label extension. *Acta Neuropsychiatrica*, 2013; 25 (1): 13.

Greenberg G, Rosenheck RA, Erickson SK, Desai RA, Stefanovics EA, Swartz M, et al. Criminal justice system involvement among people with schizophrenia. *Community Mental Health Journal*, 2011; 47 (6): 727-36.

Greenfield TK, Stoneking BC, Humphreys K, Sundby E, Bond J. A randomized trial of a mental health consumer-managed alternative to civil commitment for acute psychiatric crisis (Provisional abstract). *American Journal of Community Psychology*, 2008; 42 (1): 135-44.

Hassan L, Senior J, Webb RT, Frisher M, Tully MP, While D, et al. Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female prisoners in England. *BMC Psychiatry*, 2016; 16.

Haw C, Stubbs J. Off-label psychotropic prescribing for young persons in medium security. *Journal of Psychopharmacology*, 2010; 24 (10): 1491-98.

Havnes IA, Clausen T, Brux C, Middelthon A-L. The role of substance use and morality in violent crime - A qualitative study among imprisoned individuals in opioid maintenance treatment. *Harm Reduction Journal*, 2014; 11.

Herrera JN, Sramek JJ, Costa JF, Roy S, Heh CW, Nguyen BN. High potency neuroleptics and violence in schizophrenics. *Journal of Nervous & Mental Disease*, 1988; 176 (9): 558-61.

Janowsky DS, Shetty M, Barnhill J, Elamir B, Davis JM. Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: a retrospective, open-label, naturalistic trial. *International Journal of Neuropsychopharmacology*, 2005; 8 (1): 37-48.

Karson CN, Weinberger DR, Bigelow L, Wyatt RJ. Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. *American Journal of Psychiatry*, 1982; 139 (12): 1627-8.

Kasinathan J. Predictors of rapid reincarceration in mentally ill young offenders. *Australasian Psychiatry*, 2015; 23 (5): 550-55.

Keks N, Hill C, Sundram S, Graham A, Bellingham K, Dean B, et al. Evaluation of treatment in 35 cases of bipolar suicide. *Australian and New Zealand Journal of Psychiatry*, 2009; 43 (6): 503-08.

Kim E, Correll C, Mao L, Starr H, Alphas L. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. *CNS spectrums*, 2017; 21 (6): 466-77.

Kim SW, Grant JE, Eckert ED, Faris PL, Hartman BK. Pathological gambling and mood disorders: Clinical associations and treatment implications. *Journal of Affective Disorders*, 2006; 92 (1): 109-16.

Kinlock T, Gordon M, Schwartz R, Fitzgerald T, O'Grady K. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. *Journal of substance abuse treatment*, 2012; 37 (3): 277-85.

Kirkpatrick T, Joyce E, Milton J, Duggan C, Tyrer P, Rogers RD. Altered memory and affective instability in prisoners assessed for dangerous and severe personality disorder. *British Journal of Psychiatry*, 2007; 190s20-s26.

Kolla N, Matthews B, Wilson A, Houle S, Michael BR, Links P, et al. Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An ^{11C} Harmine Positron Emission Tomography Study. *Neuropsychopharmacology*, 2015; 40 (11): 2596-603.

Konstenius M, Jayaram N, Guterstam J, Franck J. Pharmacological treatment of ADHD with amphetamine dependence. *Acta Neuropsychiatrica*, 2013; 25 (1): 13-14.

Konstenius M, Jayaram-Lindström N, Guterstam J, Philips B, Beck O, Franck J. Methylphenidate for adhd in adults with substance dependence: A 24-week randomized placebo-controlled trial. *European Psychiatry*, 2013; 28.

Krakowski M, Czobor P. Depression and impulsivity as pathways to violence: implications for antiaggressive treatment. *Schizophrenia bulletin*, 2014; 40 (4): 886-94.

Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. *Archives of General Psychiatry*, 2006; 63 (6): 622-9.

Lee J, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. *Addiction (abingdon, england)*, 2017; 110 (6): 1008-14.

Liebrenz M, Schneider M, Buadze A, Gehring M-T, Dube A, Cafilisch C. High-dose benzodiazepine users' perceptions and experiences of anterograde amnesia. *Journal of the American Academy of Psychiatry and the Law*, 2016; 44 (3): 328-37.

Lobmaier P, Kunøe N, Gossop M, Katevoll T, Waal H. Naltrexone implants compared to methadone: outcomes six months after prison release. *European addiction research*, 2010; 16 (3): 139-45.

Luchins DJ. Carbamazepine for the violent psychiatric patient. *Lancet*, 1983; 1 (8327): 766.

Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. *Drug & Alcohol Dependence*, 2009; 99 (1): 222-30.

Martinez-Martin N, Fraguas D, Garcia-Portilla MP, Saiz PA, Bascaran MT, Arango C, et al. Self-perceived needs are related to violent behavior among schizophrenia outpatients. *Journal of Nervous & Mental Disease*, 2011; 199 (9): 666-71.

Mauri MC, Rovera C, Paletta S, De Gaspari IF, Maffini M, Altamura AC. Aggression and psychopharmacological treatments in major psychosis and personality disorders during hospitalisation. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 2011; 35 (7): 1631-5.

Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: Population based cohort study. *BMJ (Online)*, 2015; 350.

Morrissey C, Geach N, Alexander R, Chester V, Devapriam J, Duggan C, et al. Researching outcomes from forensic services for people with intellectual or developmental disabilities: a systematic review, evidence synthesis and expert and patient/carer consultation. *Health Technology Assessment*, 2017.

Morley KI, Lynskey MT, Moran P, Borschmann R, Winstock AR. Polysubstance use, mental health and high-risk behaviours: Results from the 2012 Global Drug Survey. *Drug & Alcohol Review*, 2015; 34 (4): 427-37.

Nyakyoma K, Morriss R. Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study. *Psychopharmacology Bulletin*, 2010; 43 (2): 67-81.

O'Malley GK, McHugh L, Mac Giollabhui N, Bramham J. Characterizing adult attention-deficit/hyperactivity-disorder and comorbid borderline personality disorder: ADHD symptoms, psychopathology, cognitive functioning and psychosocial factors. *European Psychiatry*, 2016; 3129-36.

Pacini M, Santucci B, Maremmani I. Requests for quetiapine from jailed substance abusers: Are they a form of abuse or self-medication in response to long-term opioid dysphoria? *Heroin Addiction and Related Clinical Problems*, 2014; 16 (1): 35-40.

Padala P, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. *International clinical psychopharmacology*, 2006; 21 (5): 275-80.

Paola A, Lincoln T, Skiest D, Desabrais M, Altice F, Springer S. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. *Contemporary clinical trials*, 2014; 39 (2): 256-68.

Procyshyn RM, Ihsan N, Thompson D. A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics. *International Clinical Psychopharmacology*, 2001; 16 (5): 291-4.

Rabinowitz J, Werbeloff N, Mandel F, Kapur S. Newmeds data on duplicate and sequential enrollment in clinical trials and online registry to reduce duplicate and sequential enrollment. *Neuropsychopharmacology*, 2016; 41S202.

Reisner AD, McGee M, Noffsinger SG. The inpatient evaluation and treatment of a self-professed budding serial killer. *International Journal of Offender Therapy & Comparative Criminology*, 2003; 47 (1): 58-70.

Resnick M, Burton BT. Droperidol vs. haloperidol in the initial management of acutely agitated patients. *Journal of Clinical Psychiatry*, 1984; 45 (7): 298-9.

Rezansoff SN, Moniruzzaman A, Fazel S, McCandless L, Somers JM. Adherence to antipsychotic medication and criminal recidivism in a canadian provincial offender population. *Schizophrenia Bulletin*, 2017; 43 (5): 1002-10.

Rossi P, Martín Subero M, García Delgar B, Fonseca Casals F, Piatti AE, Torrens Mèlich M. Drug users and antipsychotics: The role of off-label prescription. *European Neuropsychopharmacology*, 2011; 21S596-S97.

Ryback RS. Naltrexone in the treatment of adolescent sexual offenders. *Journal of Clinical Psychiatry*, 2004; 65 (7): 982-6.

Schwartz R, Kelly S, O'Grady K, Gandhi D, Jaffe J. Interim methadone treatment compared to standard methadone treatment: 4-month findings. *Journal of substance abuse treatment*, 2011; 41 (1): 21-9.

Schwoppe DM, DePriest A, Black DL, Caplan YH, Cone EJ, Heltsley R. Determining zolpidem compliance: Urinary metabolite detection and prevalence in chronic pain patients. *Journal of Analytical Toxicology*, 2014; 38 (8): 513-18.

- Shahpesandy H, Tye N, Hegarty A, Czechovska J, Kwentoh ML, Wood A. Rapid tranquillisation of acutely disturbed and violent patients: A retrospective cohort examination of 24 patients on a psychiatric intensive care unit. *Journal of Psychiatric Intensive Care*, 2015.
- Sheard M, Marini J, Bridges C, Wagner E. The effect of lithium on impulsive aggressive behavior in man. *The American journal of psychiatry*, 1976; 133 (12): 1409-13.
- Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. *Psychiatric Services*, 2007; 58 (4): 482-8.
- Spidel A, Greaves C, Yuille J, Lecomte T. A comparison of treatment adherence in individuals with a first episode of psychosis and inpatients with psychosis. *International Journal of Law and Psychiatry*, 2015; 3990-98.
- Springer S, Chen S, Altice F. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. *Journal of urban health*, 2012; 87 (4): 592-602.
- Stanford MS, Helfritz LE, Conklin SM, Villemarette-Pittman NR, Greve KW, Adams D, et al. A comparison of anticonvulsants in the treatment of impulsive aggression. *Experimental & Clinical Psychopharmacology*, 2005; 13 (1): 72-7.
- Steinert T, Sippach T, Gebhardt RP. How common is violence in schizophrenia despite neuroleptic treatment? *Pharmacopsychiatry*, 2000; 33 (3): 98-102.
- Stoychev K, Ivanov KM, Alexandrova MG, Stoychev RD. A comparison of methadone-maintained patients with and without co-occurring personality disorder. *European Neuropsychopharmacology*, 2010; 20S585.
- Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. *British Journal of Psychiatry*, 2008; 193 (1): 37-43.
- Swartz MS, Swanson JW, Wagner HR, Burns BJ, Hiday VA. Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. *Journal of Nervous & Mental Disease*, 2001; 189 (9): 583-92.
- Taylor DM, Sparshatt A, Amin F, Osborne I, Dzahini O, Hughes G, et al. Aripiprazole long-acting injection – A mirror image study of its effects on hospitalisation at one year. *Journal of Psychopharmacology*, 2017; 31 (12): 1564-69.
- Thornton LA. Criminal justice involvement among adults with severe mental illness. Vol. 71, ProQuest Information & Learning, US DB - psych DP - EBSCOhost, 2010, pp. 264-64.

Walker C, Thomas J, Allen TS. Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine. *International Journal of Offender Therapy and Comparative Criminology*, 2003; 47 (5): 556-67.

Van Dorn RA, Andel R, Boaz TL, Desmarais SL, Chandler K, Becker MA, et al. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services. *Journal of Clinical Psychiatry*, 2011; 72 (4): 502-8.

Vasic N, Segmiller F, Rees F, Jäger M, Becker T, Ormanns N, et al. Psychopharmacologic treatment of in-patients with schizophrenia: comparing forensic and general psychiatry. *Journal of Forensic Psychiatry and Psychology*, 2018; 29 (1): 1-15.

Vaughan K, McConaghy N, Wolf C, Myhr C, Black T. Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission. *Australian & New Zealand Journal of Psychiatry*, 2000; 34 (5): 801-8.

Vennemann B, Bajanowski T, Karger B, Pfeiffer H, Köhler H, Brinkmann B. Suffocation and poisoning - The hard-hitting side of Munchausen syndrome by proxy. *International Journal of Legal Medicine*, 2005; 119 (2): 98-102.

Witt K, Hawton K, Fazel S. The relationship between suicide and violence in schizophrenia: analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset. *Schizophrenia Research*, 2014; 154 (1): 61-7.

Volavka J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. *Journal of Clinical Psychiatry*, 1999; 60:43-6.

Volavka J. Violence in schizophrenia and bipolar disorder. *Psychiatria Danubina*, 2013; 25 (1): 24-33.

Vollm B, Gibbon S, Khalifa N, Duggan C, Stoffers J, Hubbard N, et al. Cochrane reviews of pharmacological and psychological interventions for antisocial personality disorder (ASPD). *European Psychiatry*, 2010; 25.

Wright N, Sheard L, Adams C, Rushforth B, Harrison W, Bound N, et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. *The British journal of general practice : the journal of the Royal College of General Practitioners*, 2011; 61 (593): e772-80.

Wright NM, French C, Allgar V. The safe implementation of a prison-based methadone maintenance programme: 7 year time-series analysis of primary care prescribing data. *BMC Family Practice*, 2014; 15:64.

Intervention

Adelugba O, Mela M, Haq I. Involuntary treatment of psychiatric inpatients certified under the Saskatchewan Mental Health Services Act in a secure forensic psychiatric treatment center. *Medicine, Science & the Law*, 2015; 55 (2): 113-20.

Bains JJS, Nielssen OB. Combining depot antipsychotic medications with novel antipsychotics in forensic patients: A practice in search of a principle. *Psychiatric Bulletin*, 2003; 27 (1): 14-16.

Bajaj N. High-dose antipsychotic prescribing: Comparison survey. *Psychiatric Bulletin*, 2008; 32 (10): 394-94.

Barr L, Wynaden D, Heslop K. Nurses' attitudes towards the use of prn psychotropic medications in acute and forensic mental health settings. *International Journal of Mental Health Nursing*, 2017.

Buscema CA, Abbasi QA, Barry DJ, Lauve TH. An algorithm for the treatment of schizophrenia in the correctional setting: the Forensic Algorithm Project. *Journal of Clinical Psychiatry*, 2000; 61 (10): 767-83.

Choong LS, Coupe T, Vijayan J. A simple clinical audit of antipsychotic medication prescribing on Hollywell Psychiatric Intensive Care Unit (PICU). *Journal of Psychiatric Intensive Care*, 2012; 8 (1): 11-14.

Connolly A, Taylor D. Factors associated with non evidence-based prescribing of antipsychotics. *Therapeutic Advances in Psychopharmacology*, 2014; 4 (6): 247-56.

Daderman AM, Edman G. Flunitrazepam abuse and personality characteristics in male forensic psychiatric patients. *Psychiatry Research*, 2001; 103 (1): 27-42.

Daderman AM, Fredriksson B, Kristiansson M, Nilsson LH, Lidberg L. Violent behavior, impulsive decision-making, and anterograde amnesia while intoxicated with flunitrazepam and alcohol or other drugs: a case study in forensic psychiatric patients. *Journal of the American Academy of Psychiatry & the Law*, 2002; 30 (2): 238-51.

De Blecourt C, Oei TI. Plasma level monitoring of antipsychotics in two different clinics for Court-order detention patients in the Netherlands. *European Neuropsychopharmacology*, 2009; 19S522-S23.

de Burca C, Miles HL, Vasquez EA. Substance use amongst mentally disordered offenders in medium security: Prevalence and relationship to offending behaviour. *Journal of Forensic Practice*, 2013; 15 (4): 259-68.

Deardorff OG. Hematological clozapine monitoring with finger prick in a forensic inpatient psychiatric hospital setting. *Journal of Pharmacy Practice*, 2015; 28 (3): 316-17.

Dolan M, Anderson IM, Deakin JFW. Relationship between 5-HT function and impulsivity and aggression in male offenders with personality disorders. *British Journal of Psychiatry*, 2001; 178352-59.

- Dolan M, Deakin WJF, Roberts N, Anderson I. Serotonergic and cognitive impairment in impulsive aggressive personality disordered offenders: Are there implications for treatment? *Psychological Medicine*, 2002; 32 (1): 105-17.
- Dornan J, Kennedy M, Garland J, Rutledge E, Kennedy HG. Functional mental capacity, treatment as usual and time: magnitude of change in secure hospital patients with major mental illness. *BMC Research Notes*, 2015; 8566.
- D'Silva K, Chadwick K, Egleston P, Milton J, Ferriter M, Abdelrazek T. Pharmacotherapy for personality disorder-prescribing practice at a high secure hospital: a preliminary report. *Personality & Mental Health*, 2013; 7 (1): 22-7.
- D'Silva K, Ferriter M. Substance use by the mentally disordered committing serious offences - A high-security hospital study. *Journal of Forensic Psychiatry and Psychology*, 2003; 14 (1): 178-93.
- Girgis S, Huckstep B, Oakley J, Ferriter M, Nikolaou V. QTc-interval abnormalities in a forensic population. *Criminal Behaviour & Mental Health*, 2007; 17 (2): 75-88.
- Gray R, Bressington D, Lathlean J, Mills A. Relationship between adherence, symptoms, treatment attitudes, satisfaction, and side effects in prisoners taking antipsychotic medication. *Journal of Forensic Psychiatry and Psychology*, 2008; 19 (3): 335-51.
- Greenall PV, Jellicoe-Jones L. Themes and risk of sexual violence among the mentally ill: Implications for understanding and treatment. *Sexual and Relationship Therapy*, 2007; 22 (3): 323-37.
- Haw C, Muthu-Veloe A, Suett M, Ibodor O, Picchioni M. Monitoring antipsychotic side effects: a completed audit cycle conducted in a secure hospital. *Journal of Forensic Practice*, 2016; 18 (3): 182-88.
- Haw C, Sasegbon H, Ismail I, Pushpanathan M. PRN medication: Beliefs and practices of psychiatrists and nurses working in PICUs and secure units. *Journal of Psychiatric Intensive Care*, 2015; 11.
- Haw C, Wolstencroft L. A study of the prescription and administration of sedative PRN medication to older adults at a secure hospital. *International Psychogeriatrics*, 2014; 26 (6): 943-51.
- Ifteni P, Szalontay AS, Teodorescu A. Reducing Restraint With Clozapine in Involuntarily Admitted Patients With Schizophrenia. *American Journal of Therapeutics*, 2017; 24 (2): e222-e26.
- Isbister G, Calver L, Page C, Stokes B, Bryant J, Downes M. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. *Annals of emergency medicine*, 2010; 56 (4): 392-401.e1.
- Johnson D, Rai S, Milne S. Olanzapine oro-dispersible (Velotab™) - An alternative to depot? *International Journal of Psychiatry in Clinical Practice*, 2002; 6 (3): 163-65.

Kageyama J, Ishii T, Hasegawa N. A statistical study on mentally disordered offenders: Comparison among substance dependent and functional psychotic offenders. *Acta Criminologiae et Medicinae Legalis Japonica*, 1998; 64 (1): 10-21.

Kamath J, Wakai S, Zhang W, Kesten K, Shelton D, Trestman R. Adaptation of the Texas Implementation Medication Algorithm for Bipolar Disorder in Adult Female Offenders. *International Journal of Offender Therapy & Comparative Criminology*, 2016; 60 (11): 1315-26.

Kamath J, Zhang W, Kesten K, Wakai S, Shelton D, Trestman R. Algorithm-driven pharmacological management of bipolar disorder in Connecticut prisons. *International Journal of Offender Therapy & Comparative Criminology*, 2013; 57 (2): 251-64.

Kasinathan J, Sharp G, Barker A. Evaluation of olanzapine pamoate depot in seriously violent males with schizophrenia in the community. *Therapeutic Advances in Psychopharmacology*, 2016; 6 (5): 301-07.

Kassen M. Delusional disorder: Treatment and the restoration of adjudicative competence. Vol. 77, ProQuest Information & Learning, US DB - psych DP - EBSCOhost, 2016.

Knecht G, Schanda H, Berner W, Morawitz I, Haubenstock E. Outpatient treatment of mentally disordered offenders in Austria. *International Journal of Law and Psychiatry*, 1996; 19 (1): 87-91.

Lea S, Callaghan L, Eick S, Heslin M, Morgan J, Bolt M, et al. The management of individuals with enduring moderate to severe mental health needs: a participatory evaluation of client journeys and the interface of mental health services with the criminal justice system in Cornwall (Structured abstract). *Health Technology Assessment Database*, 2015; (4).

Morrissey JP, Domino ME, Cuddeback GS. Expedited Medicaid enrollment, mental health service use, and criminal recidivism among released prisoners with severe mental illness. *Psychiatric Services*, 2016; 67 (8): 842-49.

Mossman D. Predicting restorability of incompetent criminal defendants. *Journal of the American Academy of Psychiatry and the Law*, 2007; 35 (1): 34-43.

Murasugi K, Tsukahara T, Washizuka S. The development and trial of a medication discontinuation program in the department of forensic psychiatry. *Annals of General Psychiatry*, 2015; 14 (1).

Murie J, Messow CM, Fitzpatrick B. Feasibility of screening for and treating vitamin D deficiency in forensic psychiatric inpatients. *Journal of Forensic and Legal Medicine*, 2012; 19 (8): 457-64.

Schindler VP. Role development: an evidenced-based intervention for individuals diagnosed with schizophrenia in a forensic facility. *Psychiatric Rehabilitation Journal*, 2005; 28 (4): 391-4.

Spitz RT. Treatment noncompliance among hospitalized forensic patients. Vol. 60, ProQuest Information & Learning, US DB - psych DP - EBSCOhost, 1999, pp. 0815-15.

Swinton M, McNamee H. Clozapine in forensic settings: persuading patients. *The British Journal of Forensic Practice*, 2003; 5 (2): 33-38.

Turner D, Basdekis-Jozsa R, Briken P. Prescription of testosterone-lowering medications for sex offender treatment in German forensic-psychiatric institutions. *Journal of Sexual Medicine*, 2013; 10 (2): 570-8.

Watanabe H. Seven-year follow-up survey on 1,108 mentally disordered offenders in 1994 - Analysis of recidivism using the classification tree approach and multilateral criminological analysis of 67 serious reoffenders. *Acta Criminologicae et Medicinae Legalis Japonica*, 2005; 71 (5): 133-63.

Not primary studies

A. Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders. Part I: Unique patient populations. *Journal of Clinical Psychiatry*, 1998; 59 (5): 259-65.

A. Medication-induced violence others towards. *Prescrire International*, 2014; 23 (150): 153-5.

Albrecht B, Staiger PK, Best D, Hall K, Nielsen S, Lubman DI, et al. Benzodiazepine use of community-based violent offenders: a preliminary investigation. *Journal of Substance Use*, 2016;1-9.

Appelbaum KL. Attention deficit hyperactivity disorder in prison: A treatment protocol. *Journal of the American Academy of Psychiatry and the Law*, 2009; 37 (1): 45-49.

Arlie DM, Chappel JN, Thienhaus OJ, Piasecki M, Thienhaus OJ, Piasecki M. Treating intoxication and withdrawal. Civic Research Institute, 2007.

Belli H, Ural C. The association between schizophrenia and violent or homicidal behaviour: the prevention and treatment of violent behaviour in these patients. *West Indian Medical Journal*, 2012; 61 (5): 538-43.

Bourget D, Labelle A. Managing pathologic aggression in people with psychotic disorders. *Journal of Psychiatry & Neuroscience*, 2012; 37 (2): E3-4.

Brooman-White R, Simpson P, Hotham J, Das M. Amisulpride augmentation of clozapine in violent schizophrenia patients: A case-series from the United Kingdom. *European neuropsychopharmacology*, 2013; 23S487-s88.

Buckley PF, Kausch O, Gardner G. Clozapine treatment of schizophrenia: Implications for forensic psychiatry. *Journal of Clinical Forensic Medicine*, 1995; 2 (1): 9-16.

Buckley PF, Noffsinger SG, Smith DA, Hrouda DR, Knoll JLt. Treatment of the psychotic patient who is violent. *Psychiatric Clinics of North America*, 2003; 26 (1): 231-72.

Caniato RN, Gundabawady A, Baune BT, Alvarenga ME. Malingered psychotic symptoms and quetiapine abuse in a forensic setting. *Journal of Forensic Psychiatry and Psychology*, 2009; 20 (6): 928-35.

Cantor C, Jones D. Intravenous sedation of involuntary psychiatric patients in New South Wales. *Australian & New Zealand Journal of Psychiatry*, 1998; 32 (1): 141-3.

Citrome L, Volavka J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. *CNS Drugs*, 2011; 25 (12): 1009-21.

Citrome L, Volavka J. The psychopharmacology of violence: making sensible decisions. *Cns Spectrums*, 2014; 19 (5): 411-8.

Citrome L. Atypical antipsychotics for the management of agitation and aggression: An update. *International Journal of Neuropsychopharmacology*, 2014; 1722.

Crome IB, Myton T. Pharmacotherapy in dual diagnosis. *Advances in Psychiatric Treatment*, 2004; 10 (6): 413-24.

Dardashti LJ, O'Day JA, Barsom MW, Schwartz EH, Proctor GJ. Illustrative cases to support the Cal-VAT guidelines. *Cns Spectrums*, 2015; 20 (3): 311-8.

Dervaux A, Artiges E. Olanzapine for violent schizophrenia and Klinefelter syndrome. *American Journal of Psychiatry*, 2002; 159 (3): 493-4.

Dute J. Compulsory medication within the prison system. *Medicine & Law*, 2001; 20 (2): 221-6.

Eilers R. Antihostility effects of adjunctive divalproex. *Psychiatric Services*, 2004; 55 (9): 1068; author reply 68-9.

Elliott C, Lamkin M. Restrict the Recruitment of Involuntarily Committed Patients for Psychiatric Research. *JAMA Psychiatry*, 2016; 73 (4): 317-8.

Fazel S, Zetterqvist J, Larsson H, Långström N, Lichtenstein P. Antipsychotics, mood stabilisers, and risk of violent crime. *The Lancet*, 2014; 384 (9949): 1206-14.

Ferziger R, Alphs L, Turner N, Mao L, Rodriguez S, Dixon L, et al. A multicenter effectiveness study of paliperidone palmitate vs oral antipsychotics for people with schizophrenia recently released from jail: Study rationale and methodology. *Neuropsychopharmacology*, 2010; 35S101-S02.

Ferziger R, Alphs L, Turner N, Mao L, Rodriguez S, Dixon L, et al. Paliperidone palmitate vs. oral antipsychotics for people with schizophrenia recently released from jail: Rationale and methodology. *Schizophrenia Bulletin*, 2011; 37302-03.

Fontanarosa J, Uhl S, Oyesanmi O, Schoelles K. Interventions for adult offenders with serious mental illness (Structured abstract). *Health Technology Assessment Database*, 2013; (4).

Ginsberg Y, Långström N, Larsson H, Lichtenstein P. ADHD and criminality: Could treatment benefit prisoners with ADHD who are at higher risk of reoffending? *Expert Review of Neurotherapeutics*, 2013; 13 (4): 345-48.

Ginsberg Y. Pharmacological treatment of offenders with ADHD. *ADHD Attention Deficit and Hyperactivity Disorders*, 2015; 7S4.

Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. *Journal of Clinical Psychiatry*, 1998; 598-14.

Goff ML. Protecting our mentally ill: a critique of the role of Indiana state courts in protecting involuntarily committed mental patients' right to refuse medication. *Indiana Law Journal*, 2001; 76 (4): 983-1000.

Grann M, Langstrom N, Yourstone J, Freij I, Kullgren G, Forsman A, et al. Psychiatric risk assessment methods: are violent acts predictable? A systematic review (Structured abstract). *Health Technology Assessment Database*, 2005; (4).

Hefazi E, Johnson B, Chen-Peng L, Lee K. Metabolic syndrome monitoring for inmate-patients prescribed antipsychotic therapy. *Pharmacotherapy*, 2015; 35 (11): e208.

Hoffmann O, Mossberg L, Heine L. [Benzodiazepine treatment in criminal medicine: Careful control and strong indications are required]. *Lakartidningen*, 2006; 103 (28): 2131-4.

Hucker S. Forensic psychiatry. *Canadian Journal of Psychiatry*, 1998; 43 (5): 456-57.

Jayakody K, Gibson RC, Kumar A, Gunadasa S. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. *Cochrane Database of Systematic Reviews*, 2012; (4): CD000525.
Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. *Journal of Addiction Medicine*, 2015; 9 (5): 358-67.

Kennedy HG, Mikhail SW. Advantages of depot antipsychotics. *Lancet*, 2000; 356 (9229): 594.
Khan O, Ferriter M, Huband N, Powney MJ, Dennis JA, Duggan C. Pharmacological interventions for those who have sexually offended or are at risk of offending. *Cochrane Database of Systematic Reviews*, 2015; (2): CD007989.

Konstenius M, Jayaram-Lindström N, Guterstam J, Beck O, Philips B, Franck J. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. *Addiction (abingdon, england)*, 2013; 109 (3): 440-49.

Konstenius M, Jayaram-Lindström N, Guterstam J, Beck O, Philips B, Franck J. 'Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: A 24-week randomized placebo-controlled trial': Corrigendum. *Addiction*, 2014; 109 (9): 1571-72.

Kraus JE, Sheitman BB. Clozapine reduces violent behavior in heterogeneous diagnostic groups. *Journal of Neuropsychiatry & Clinical Neurosciences*, 2005; 17 (1): 36-44.

Kravitz HM, Davis JM, Silberberg J. Reducing recidivism among mentally ill offenders: The role of psychotropic medication in correctional psychiatry. *Psychiatric Annals*, 2001; 31 (7): 409-18.

Lader M. The risks of rapid tranquilization. *Clinical Risk*, 2002; 8 (6): 232-36.

Lee CT. Medication adherence, rates of rehospitalization, and depot medications in forensic patients with a diagnosis of schizophrenia. Vol. 71, ProQuest Information & Learning, US DB - psych DP - EBSCOhost, 2010, pp. 224-24.

Lee R, Coccaro E. The neuropsychopharmacology of criminality and aggression. *Canadian Journal of Psychiatry*, 2001; 46 (1): 35-44.

Lewis CF. Successfully treating aggression in mentally ill prison inmates. *Psychiatric Quarterly*, 2000; 71 (4): 331-43.

Lin I, Muser E, Munsell M, Benson C, Menzin J. Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis. *Journal of Medical Economics*, 2015; 18 (3): 219-29.

Lindqvist P, Skipworth J. Finding the evidence in forensic rehabilitation [4]. *British Journal of Psychiatry*, 2000; 177372.

Meyer JM. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. *Cns Spectrums*, 2014; 19 (5): 432-8.

Mikhail SW, Kennedy HG. Homicide, novel antipsychotics, and non-compliance. *Lancet*, 2000; 355 (9210): 1189-90.

Milton J, Lawton J, Smith M, Buckley A. Hidden high-dose antipsychotic prescribing: Effects of p.r.n. doses. *Psychiatric Bulletin*, 1998; 22 (11): 675-77.

Monroe R. Anticonvulsants in the treatment of aggression. *The Journal of nervous and mental disease*, 1975; 160 (2): 119-26.

Morana HCP, Stone MH, Abdalla-Filho E. Personality disorders, psychopathy, and serial killers. *Revista Brasileira de Psiquiatria*, 2006; 28S74-S79.

- Morrisette DA, Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. *Cns Spectrums*, 2014; 19 (5): 439-48.
- Mosescu M, Bragau M, Popescu A. Effectiveness of haloperidol, olanzapine and quetiapine in reducing aggressive behaviour in forensic in-patients with schizophrenia. *European Neuropsychopharmacology*, 2011; 21S490.
- Oosterhuis H. Treatment as punishment: Forensic psychiatry in the netherlands (1870-2005). *International Journal of Law and Psychiatry*, 2014; 37 (1): 37-49.
- Parker C. A brief summary of loxapine inhalation for rapid tranquillisation: What is its place in practice? *Journal of Psychiatric Intensive Care*, 2014; 10 (2): 110-14.
- Parker C. Midazolam for rapid tranquillisation: Its place in practice. *Journal of Psychiatric Intensive Care*, 2015; 11 (1): 66-72.
- Pow JL, Baumeister AA, Hawkins MF, Cohen AS, Garand JC. Deinstitutionalization of American public hospitals for the mentally ill before and after the introduction of antipsychotic medications. *Harvard Review of Psychiatry*, 2015; 23 (3): 176-87.
- Quanbeck C. Forensic Psychiatric Aspects of Inpatient Violence. *Psychiatric Clinics of North America*, 2006; 29 (3): 743-60.
- Quinn J, Kolla NJ. From Clozapine to Cognitive Remediation: A Review of Biological and Psychosocial Treatments for Violence in Schizophrenia. *Canadian Journal of Psychiatry*, 2017; 62 (2): 94-101.
- Shader RI, Jackson AH, Dodes LM. The antiaggressive effects of lithium in man. *Psychopharmacologia*, 1974; 40 (1): 17-24.
- Sherak DL. Pharmacological treatment of sexually offending behavior in people with mental retardation/developmental disabilities. *Mental Health Aspects of Developmental Disabilities*, 2000; 3 (2): 62-74.
- Shindul-Rothschild J, Rothschild AJ. Benzodiazepine response. *American Journal of Nursing*, 2001; 101 (11): 13-4.
- Singh H, Dubin WR, Kaur S. Drug interactions affecting clozapine levels. *Journal of Psychiatric Intensive Care*, 2015; 11 (1): 52-65.
- Soyka M. Antipsychotic treatment of schizophrenics at risk for violence. *Pharmacopsychiatry*, 2001; 34 (1): 43-4.
- Stahl SM, Morrisette DA, Cummings M, Azizian A, Bader S, Broderick C, et al. California State Hospital Violence Assessment and Treatment (Cal-VAT) guideline. *Cns Spectrums*, 2014; 19 (5): 449-65.

Stanford MS, Anderson NE, Lake SL, Baldrige RM. Pharmacologic treatment of impulsive aggression with antiepileptic drugs. *Current Treatment Options in Neurology*, 2009; 11 (5): 383-90.

Stone DC, Niz DO. Treatment considerations in the forensic patient with schizophrenia. *Current Pharmaceutical Design*, 2004; 10 (18): 2263-7.

Strah A, Petre M, Koprivšek J, Mrhar A. Therapeutic drug monitoring of valproate: Is there a rationale for it? *International Journal of Clinical Pharmacy*, 2017; 39 (1): 340-41.

Stubbs JH, Haw CM. Medication, schizophrenia and the forensic multidisciplinary team. *The British Journal of Forensic Practice*, 2001; 3 (4): 29-33.

Tavcar R, Dernovsek MZ. Antipsychotic drugs and risk of homicide. *Lancet*, 2000; 355 (9220): 2073.
Tiihonen J, Pinard G-F, Pagani L, Pinard G-F, Pagani L. *Recidivistic violent behavior and Axis I and Axis II disorders*. Cambridge University Press, 2001.

Tsoelas C, Tzeferakos G, Kotsioubas I, Kalemis G, Douzenis A. Use of long acting injectables in mentally disordered offenders. *European Neuropsychopharmacology*, 2016; 26S520-S21.

Wakefield TP. The combined pharmacotherapy controversy. *Journal of the American Academy of Child & Adolescent Psychiatry*, 1996; 35 (1): 1-2.

Wehring HJ, Carpenter WT. Violence and schizophrenia. *Schizophrenia Bulletin*, 2011; 37 (5): 877-78.

West S. A review of chemical castration and its use in the U.S. penal system. *American Journal of Forensic Psychiatry*, 2006; 27 (1): 55-70.

Westreich LM. Medication of criminal defendants. *Journal of the American Academy of Psychiatry & the Law*, 2001; 29 (4): 504.

Winchel RM, Stanley M. Self-injurious behavior: a review of the behavior and biology of self-mutilation. *American Journal of Psychiatry*, 1991; 148 (3): 306-17.

Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. *International Journal of Clinical Practice*, 2008; 62 (8): 1237-45.

Volavka J. Clozapine is gold standard, but questions remain. *International Journal of Neuropsychopharmacology*, 2012; 15 (9): 1201-04.

Young JL, Spitz RT, Hillbrand M, Daneri G. Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects. *Journal of the American Academy of Psychiatry & the Law*, 1999; 27 (3): 426-44.

Incorrect outcome

Ahmed U, Brown A. Lipid monitoring of patients taking clozapine in a high secure forensic hospital. *European Psychiatry*, 2011; 26.

Muser E, Kozma CM, Benson CJ, Mao L, Starr HL, Alphs L, et al. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement. *Journal of Medical Economics*, 2015; 18 (8): 637-45.

Parker J, De Villiers J, Churchward S. High-dose antipsychotic drug use in a forensic setting. *Journal of Forensic Psychiatry*, 2002; 13 (2): 407-15.

Stone-Brown K, Naji M, Francioni A, Myers K, Samarendra H, Mushtaq-Chaudhry H, et al. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital. *Cns Spectrums*, 2016; 21 (1): 60-9.

Barrett B, Byford S, Seivewright H, Cooper S, Duggan C, Tyrer P. The assessment of dangerous and severe personality disorder: service use, cost, and consequences (Structured abstract). *Journal of Forensic Psychiatry and Psychology*, 2009; 20 (1): 120-31.

Barrett B, Byford S. Costs and outcomes of an intervention programme for offenders with personality disorders (Structured abstract). *British Journal of Psychiatry*, 2012; 200 (4): 336-41.

No Control group

Baruch N, Das M, Sharda A, Basu A, Bajorek T, Ross CC, et al. An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital. *Therapeutic Advances in Psychopharmacology*, 2014; 4 (5): 186-92.

Brown D, Larkin F, Sengupta S, Romero-Ureclay JL, Ross CC, Gupta N, et al. Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. *Cns Spectrums*, 2014; 19 (5): 391-402.

Ebrahim GM, Gibler B, Gacono CB, Hayes G. Patient response to clozapine in a forensic psychiatric hospital. *Hospital and Community Psychiatry*, 1994; 45 (3): 271-73.

Fagan AL, Kissack JC, Augustin BG. Adverse events medication treatment costs in a chronically, severely mentally ill forensics population. *Clinical Schizophrenia and Related Psychoses*, 2008; 2 (2): 158-62.

Foley TR, Goldenberg EE, Bartley F, Gayda E. The development of a clozapine treatment program for offenders in a correctional mental health prison. *International Journal of Offender Therapy and Comparative Criminology*, 1995; 39 (4): 353-58.

Gibbon S, Silva E, Kaler R, Qurashi I, Das M, Patrick J, et al. Risperidone long-acting injection (RLAI) - real world outcomes from the United Kingdom high-secure hospitals. *The British Journal of Forensic Practice*, 2011; 13 (4): 264-69.

Gilchrist A, Taylor M, Wright M, Drury K, Short A, Steel R, et al. Is olanzapine clinically effective? A naturalistic outcome survey in two hospital settings. *Pharmaceutical Journal*, 2002; 269 (7211): 222-25.

Haw C, Stubbs J, Gibbon S. A survey of the use of emergency parenteral medication at a secure psychiatric hospital. *Journal of Psychiatric Intensive Care*, 2013; 9 (2): 77-84.

Haw C, Wolstencroft L. A study of the use of sedative PRN medication in patients at a secure hospital. *Journal of Forensic Psychiatry and Psychology*, 2014; 25 (3): 307-20.

Hilton NZ, Ham E, Lang C, Harris GT. Weight gain and its correlates among forensic inpatients. *The Canadian Psychiatric Association Journal / La Revue de l'Association des psychiatres du Canada*, 2015; 60 (5): 232-38.

Hotham JE, Simpson PJ, Brooman-White RS, Basu A, Ross CC, Humphreys SA, et al. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. *Cns Spectrums*, 2014; 19 (5): 403-10.

Kerepic I, Koludrovic M, Jurin M, Stracenski M, Kondres N, Magerle A. Clozapine in treatment of schizophrenic heteroaggressive forensic patients. *Psychiatria Danubina*, 1994; 6 (1): 105-08.

Mortlock AM, Larkin F, Ross CC, Gupta N, Sengupta S, Das M. Effectiveness of paliperidone depot injection in seriously violent men with comorbid schizophrenia and dissocial personality disorder in a UK high-security hospital. *Therapeutic Advances in Psychopharmacology*, 2017; 7 (5): 169-79.

Ojala K, Niskanen L, Tiihonen J, Paavola P, Putkonen A, Repo-Tiihonen E. Characterization of metabolic syndrome among forensic psychiatric inpatients. *Journal of Forensic Psychiatry and Psychology*, 2008; 19 (1): 33-51.

Qurashi I, Stephenson P, Chu S, Duffy C, Husain N, Chaudhry I. An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service. *Therapeutic Advances in Psychopharmacology*, 2015; 5 (3): 146-50.

Salem A, Kushnier A, Dorio N, Reeves R. Nonemergency Involuntary Antipsychotic Medication in Prison: Effects on Prison Inpatient Days and Disciplinary Charges. *Journal of the American Academy of Psychiatry & the Law*, 2015; 43 (2): 159-64.

Smith EN, Durge V, Sengupta S, Das M. Asenapine augmentation and treatment-resistant schizophrenia in the high-secure hospital setting. *Therapeutic Advances in Psychopharmacology*, 2014; 4 (5): 193-97.

Witzel JG, Gubka U, Weisser H, Bogerts B. Antipsychotic polypharmacy in the emergency treatment of highly aggressive schizophrenic prisoners - a retrospective study. *International journal of prison health.*, 2008; 4 (2): 96-103.

Language

Steinert T. Mental disorder, criminality and violence: Knowledge and consequences. *Recht und Psychiatrie*, 2001; 19 (2): 89-96.

Ying Y-F, Xu S-Q, Liu X-X, Ye J-H, Cao J. Clinical controlled study on quetiapine and clozapine combined with lithium in patients with mania. [Chinese]. *Chinese Pharmaceutical Journal*, 2007; 42 (11): 877-8.

Duplicate

Allen MH, Debanne M, Lazignac C, Adam E, Dickinson LM, Damsa C. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. *American Journal of Psychiatry*, 2011; 168 (4): 395-9.

Brooman-White R, Simpson P, Hotham J, Das M. Amisulpride augmentation of clozapine in violent schizophrenia patients: A case-series from the United Kingdom. *European Neuropsychopharmacology*, 2013; 23S487-S88.

Brown CR. The use of benzodiazepines in prison populations. *Journal of Clinical Psychiatry*, 1978; 39 (3): 219-22.

Collins PJ, Larkin EP, Schubsachs APW. Lithium carbonate in chronic schizophrenia - A brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. *Acta Psychiatrica Scandinavica*, 1991; 84 (2): 150-54.

Collins PJ, Larkin EP, Shubsachs AP. Lithium carbonate in chronic schizophrenia: A brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. *Acta Psychiatrica Scandinavica*, 1991; 84 (2): 150-54.

Collins PJ, Larkin EP, Shubsachs AP. Lithium carbonate in chronic schizophrenia--a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. *Acta Psychiatrica Scandinavica*, 1991; 84 (2): 150-4.

D'Silva K, Chadwick K, Egleston P, Milton J, Ferriter M, Abdelrazek T. Pharmacotherapy for personality disorder—Prescribing practice at a high secure hospital: A preliminary report. *Personality and Mental Health*, 2013; 7 (1): 22-27.

Ebrahim GM, Gibler B, Gacono CB, Hayes G. 'Patient response to clozapine in a forensic psychiatric hospital': Correction. *Hospital & Community Psychiatry*, 1994; 45 (5): 500-00.

Ginsberg Y, Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. *The British journal of psychiatry : the journal of mental science*, 2012; 200 (1): 68-73.

Ginsberg Y, Långström N, Larsson H, Lindefors N. Long-Term Treatment Outcome in Adult Male Prisoners with Attention-Deficit/Hyperactivity Disorder: Three-Year Naturalistic Follow-Up of a 52-Week Methylphenidate Trial. *Journal of Clinical Psychopharmacology*, 2015; 35 (5): 535-43.

Gobbi G, Comai S, Debonnel G. Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: A pilot randomized, open-label, comparative study. *Neuropsychiatric disease and treatment*, 2014; 10757-65.

Isbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. *Annals of Emergency Medicine*, 2010; 56 (4): 392-401.e1.

Kolla NJ, Matthews B, Wilson AA, Houle S, Michael Bagby R, Links P, et al. Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An ¹¹C-Harmine Positron Emission Tomography Study. *Neuropsychopharmacology*, 2015; 40 (11): 2596-603.

Krakowski MI, Czobor P. Depression and impulsivity as pathways to violence: implications for antiaggressive treatment. *Schizophrenia Bulletin*, 2014; 40 (4): 886-94.

Monroe RR. Anticonvulsants in the treatment of aggression. *Journal of Nervous & Mental Disease*, 1975; 160 (2): 119-26.

Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. *American Journal of Psychiatry*, 1976; 133 (12): 1409-13.

Stanford M, Helfritz L, Conklin S, Villemarette-Pittman N, Greve K, Adams D, et al. A comparison of anticonvulsants in the treatment of impulsive aggression. *Experimental and clinical psychopharmacology*, 2005; 13 (1): 72-7.

Swanson J, Swartz M, Dorn R, Volavka J, Monahan J, Stroup T, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. *The British journal of psychiatry : the journal of mental science*, 2008; 193 (1): 37-43.

Benefits and risks, systematic reviews about relevant co-morbidity

Population

Baandrup L, Ostrup Rasmussen J, Klokke L, Austin S, Bjornshave T, Fuglsang Bliksted V, et al. Treatment of adult patients with schizophrenia and complex mental health needs - A national clinical guideline. *Nordic Journal of Psychiatry*, 2016; 70 (3): 231-40.

Barnard AL, Young AH, Pearson ADJ, Geddes J, O'Brien G. A systematic review of the use of atypical antipsychotics in autism. *Journal of Psychopharmacology*, 2002; 16 (1): 93-101.

Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: A systematic review. *JAMA: Journal of the American Medical Association*, 2016; 315 (18): 1997-2008.

Clark C, Burge MR. Diabetes mellitus associated with atypical anti-psychotic medications. *Diabetes Technology & Therapeutics*, 2003; 5 (4): 669-83.

Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. *International Journal of Neuropsychopharmacology*, 2014; 17 (7): 1083-93.

Fung LK, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, et al. Pharmacologic treatment of severe irritability and problem behaviors in Autism: A systematic review and meta-analysis. *Pediatrics*, 2016; 137S124-S35.

Gillies D, Sampson S, Beck A, Rathbone J. Benzodiazepines for psychosis-induced aggression or agitation. 2013; (4).

Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. *Cochrane Database of Systematic Reviews*, 2007; (1).

Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. *American Journal of Psychiatry*, 2002; 159 (2): 180-90.

Lindenmayer JP, Kaur A. Antipsychotic Management of Schizoaffective Disorder: A Review. *Drugs*, 2016; 76 (5): 589-604.

Masood B, Lepping P, Romanov D, Poole R. Treatment of Alcohol-Induced Psychotic Disorder (Alcoholic Hallucinosi)s-A Systematic Review. *Alcohol and alcoholism (Oxford, Oxfordshire)*, 2017;1-9.

Mortimer AM. Update on the management of symptoms in schizophrenia: Focus on amisulpride. *Neuropsychiatric Disease and Treatment*, 2009; 5 (1): 267-77.

Pillay J, Boylan K, Carrey N, Newton A, Vandermeer B, Nuspl M, et al. 2017.

Wrong intervention

Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane database of systematic reviews, 2018; 1CD008074.

Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database of Systematic Reviews, 2013; 2017 (12).

Zaman H, Sampson SJ, Beck AL, Sharma T, Clay FJ, Spyridi S, et al. Benzodiazepines for psychosis-induced aggression or agitation. The Cochrane database of systematic reviews, 2017; 12CD003079.

Not a systematic review

Baker AL, Thornton LK, Hides L, Dunlop A. Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials. *Current Pharmaceutical Design*, 2012; 18 (32): 4923-37.

Belli H, Ural C. The association between schizophrenia and violent or homicidal behaviour: The prevention and treatment of violent behaviour in these patients. *West Indian Medical Journal*, 2012; 61 (5): 538-43.

Crockford D, Addington D. Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders. *Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie*, 2017; 62 (9): 624-34.

Elbe D, Lalani Z. Review of the pharmacotherapy of irritability of autism. *Journal of the Canadian Academy of Child and Adolescent Psychiatry*, 2012; 21 (2): 130-46.

Frogley CL, Taylor D, Piccioni M. A systematic review of the evidence of clozapine's anti-aggressive effects. *Schizophrenia Research*, 2012; 136S358.

Galling B, Roldán A, Correll CU. Antipsychotic polypharmacy in schizophrenia: Results from a systematic review and meta-analysis of augmentation with a second antipsychotic. *European Neuropsychopharmacology*, 2015; 25S499.

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. *World Journal of Biological Psychiatry*, 2015; 16 (3): 142-70.

Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. *Addictive Behaviors*, 2012; 37 (1): 11-24.

Koola MM, Wehring HJ, Kelly DL. The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. *Journal of Dual Diagnosis*, 2012; 8 (1): 50-61.

Levy E, Traicu A, Iyer S, Malla A, Joober R. Psychotic disorders comorbid with attention-deficit hyperactivity disorder: an important knowledge gap. *Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie*, 2015; 60 (3): S48-52.

Marini S, Cinosi E, Acciavatti T, Lupi M, Di Iorio G, Sepede G, et al. Mood stabilizers in the treatment of impulsive behavioral dyscontrol in borderline personality disorder: A systematic review. *European Neuropsychopharmacology*, 2014; 24S742.

Topiwala A, Fazel S. The pharmacological management of violence in schizophrenia: a structured review. *Expert Review of Neurotherapeutics*, 2011; 11 (1): 53-63.

Volavka J. Violence in schizophrenia and bipolar disorder. *Psychiatria Danubina*, 2013; 25 (1): 24-33.

Zhang J, Lencz T, Robinson D, Fleischhacker W, Kahn R, Ophoff R, et al. Pharmacogenetic associations of antipsychotic drug induced weight gain: A systematic review and meta-analysis. *Neuropsychopharmacology*, 2014; 39S418-S19.

Outcome

Duggan L, Brylewski J. Antipsychotic medication versus placebo for people with both schizophrenia and learning disability. *Cochrane Database of Systematic Reviews*, 2004; (4).

Duplex

Duggan L, Brylewski J. Antipsychotic medication for those with both schizophrenia and learning disability. *Cochrane Database of Systematic Reviews*, 2000; (2): CD000030.

Duggan L, Brylewski J. Antipsychotic medication for those with both schizophrenia and learning disability. *Cochrane Database of Systematic Reviews*, 2001; (3): CD000030.

Duggan L, Brylewski J. Antipsychotic medication versus placebo for people with both schizophrenia and learning disability. *Cochrane Database of Systematic Reviews*, 2009; (4).

Duggan L, Brylewski J. Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review. *Journal of Intellectual Disability Research*, 1999; 4394-104.

Hjorthøj C, Fohlmann A, Nordentoft M. Reprint of "Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - A systematic review". *Addictive Behaviors*, 2009; 34 (10): 846-51.

Hjorthøj C, Fohlmann A, Nordentoft M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders—A systematic review. *Addictive Behaviors*, 2009; 34 (6): 520-25.

Too low quality (high risk of bias)

Azarin JM, Simon N, Adida M, Belzeaux R. Pharmacological treatment of schizophrenia with comorbid substance use disorder. *Expert Opinion on Pharmacotherapy*, 2016; 17 (2): 231-53.

Baker AL, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic or depressive disorders: A systemic review. *Journal of Clinical Psychiatry*, 2010; 71 (3): 247-54.

Bellino S, Rinaldi C, Bozzatello P, Bogetto F. Pharmacotherapy of borderline personality disorder: a systematic review for publication purpose. *Current Medicinal Chemistry*, 2011; 18 (22): 3322-9.

Bennett ME, Bradshaw KR, Catalano LT. Treatment of substance use disorders in schizophrenia. *American Journal of Drug & Alcohol Abuse*, 2017; 43 (4): 377-90.

Duggan C, Huband N, Smailagic N, Ferriter M, Adams C. The use of pharmacological treatments for people with personality disorder: A systematic review of randomized controlled trials. *Personality and Mental Health*, 2008; 2 (3): 119-70.

Hjorthoj C, Fohlmann A, Nordentoft M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review. *Addictive Behaviors*, 2009; 34 (6): 520-5.

Quinn J, Kolla NJ. From Clozapine to Cognitive Remediation: A Review of Biological and Psychosocial Treatments for Violence in Schizophrenia. *Canadian Journal of Psychiatry*, 2017; 62 (2): 94-101.

Rosenbluth M, Sinyor M. Off-label use of atypical antipsychotics in personality disorders. *Expert Opinion on Pharmacotherapy*, 2012; 13 (11): 1575-85.

Victoroff J, Coburn K, Reeve A, Sampson S, Shillcutt S. Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. *Journal of Neuropsychiatry & Clinical Neurosciences*, 2014; 26 (4): 283-312.

Wobrock T, Soyka M. Pharmacotherapy of patients with schizophrenia and substance abuse. *Expert Opinion on Pharmacotherapy*, 2009; 10 (3): 353-67.

Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder--reviewing the evidence and clinical recommendations. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 2008; 32 (6): 1375-85.

Experiences

Wrong population

Barr L, Wynaden D, Heslop K. Nurses' attitudes towards the use of PRN psychotropic medications in acute and forensic mental health settings. *International Journal of Mental Health Nursing*, 2017; 2424.

Bentley KJ, Casey RC. Incarcerated Women's Experiences and Beliefs About Psychotropic Medication: An Empirical Study. *Psychiatric Services*, 2017; 68 (4): 384-89.

Borchers P, Seikkula J, Arnkil T. The need-adapted approach in psychosis: The impact of psychosis on the treatment and the professionals. *Ethical Human Psychology and Psychiatry*, 2014; 16 (1): 5-19.

Bowen RA, Rogers A, Shaw J. Medication management and practices in prison for people with mental health problems: a qualitative study. *International Journal of Mental Health Systems*, 2009; 3 (1): 24.

Casey RC, Bentley KJ. Psychotropic Medication Experiences of Incarcerated Women: A Qualitative Inquiry into Conundrums of Access and Identity. *Women and Criminal Justice*, 2017;1-13.

Gault I. Service-user and carer perspectives on compliance and compulsory treatment in community mental health services. *Health & Social Care in the Community*, 2009; 17 (5): 504-13.

Georgieva I, Mulder CL, Wierdsma A. Patients' preference and experiences of forced medication and seclusion. *Psychiatric Quarterly*, 2012; 83 (1): 1-13.

Goodwin I, Holmes G, Newnes C, Waltho D. A qualitative analysis of the views of in-patient mental health service users. *Journal of Mental Health*, 1999; 8 (1): 43-54.

Greenberg WM, Moore-Duncan L, Herron R. Patients' attitudes toward having been forcibly medicated. *Bulletin of the American Academy of Psychiatry & the Law*, 1996; 24 (4): 513-24.

Hamann J, Mendel RT, Fink B, Pfeiffer H, Cohen R, Kissling W. Patients' and psychiatrists' perceptions of clinical decisions during schizophrenia treatment. *Journal of Nervous & Mental Disease*, 2008; 196 (4): 329-32.

Hassan L, Edge D, Senior J, Shaw J. Accounting for psychotropic medication changes in prisons: patient and doctor perspectives. *Qualitative Health Research*, 2015; 25 (7): 954-65.

Hassan L, Edge D, Senior J, Shaw J. Staff and patient perspectives on the purpose of psychotropic prescribing in prisons: care or control? *General Hospital Psychiatry*, 2013; 35 (4): 433-8.

Haw C, Stubbs J, Dickens G. Medicines management: an interview study of nurses at a secure psychiatric hospital. *Journal of Advanced Nursing*, 2015; 71 (2): 281-94.

Haw C, Stubbs J. Combined antipsychotics for 'difficult-to-manage' and forensic patients with schizophrenia: Reasons for prescribing and perceived benefits. *Psychiatric Bulletin*, 2003; 27 (12): 449-52.

- Haw C, Stubbs J. Medication for borderline personality disorder: a survey at a secure hospital. *International Journal of Psychiatry in Clinical Practice*, 2011; 15 (4): 280-5.
- Haw CM, Stubbs JH, Dickens GL. Nurses' views about unlicensed and off-license medicines in forensic mental health. *Journal of Forensic Practice*, 2014; 16 (3): 194-202.
- Hughes R, Hayward M, Finlay WML. Patients' perceptions of the impact of involuntary inpatient care on self, relationships and recovery. *Journal of Mental Health*, 2009; 18 (2): 152-60.
- Iversen VC, Sallaup T, Vaaler AE, Helvik A-S, Morken G, Linaker O. Patients' perceptions of their stay in a psychiatric seclusion area. *Journal of Psychiatric Intensive Care*, 2011; 7 (1): 1-10.
- Jaeger S, Pfiffner C, Weiser P, Langle G, Croissant D, Schepp W, et al. Long-term effects of involuntary hospitalization on medication adherence, treatment engagement and perception of coercion. *Social Psychiatry & Psychiatric Epidemiology*, 2013; 48 (11): 1787-96.
- Lee CC, Connolly PM, Dietz EO. Forensic nurses' views regarding medications for inmates. *Journal of Psychosocial Nursing & Mental Health Services*, 2005; 43 (6): 32-9.
- Machin A, McCarthy L. Antipsychotic prescribing of consultant forensic psychiatrists working in different levels of secure care with patients with schizophrenia. *Psychiatrist*, 2017; 41 (2): 103-08.
- Martean L, Evans C. Prescribing for personality disorder: Qualitative study of interviews with general and forensic consultant psychiatrists. *Psychiatric Bulletin*, 2014; 38 (3): 116-21.
- Paton C, Garcia JA, Brooke D. Use of atypical antipsychotics by consultant psychiatrists working in forensic settings. *Psychiatric Bulletin*, 2002; 26 (5): 172-74.
- Perry A, Gilbody S. User-defined outcomes in mental health: a qualitative study and consensus development exercise. *Journal of Mental Health*, 2009; 18 (5): 415-23.
- Sowerby C, Taylor D. Cross-sector user and provider perceptions on experiences of shared-care clozapine: a qualitative study. *BMJ open*, 2017; 7 (9): e017183.
- Strudwick G, Clark C, McBride B, Sakal M, Kalia K. Thank you for asking: Exploring patient perceptions of barcode medication administration identification practices in inpatient mental health settings. *International journal of medical informatics*, 2017; 10531-37.
- Wolfson PM, Paton C. Clozapine audit: what do patients and relatives think? *Journal of Mental Health*, 1996; 5 (3): 267-73.
- Vuckovich PK, Artinian BM. Justifying coercion. *Nursing Ethics*, 2005; 12 (4): 370-80.
- Völlm BA, Chadwick K, Abdelrazek T, Smith J. Prescribing of psychotropic medication for personality disordered patients in secure forensic settings. *Journal of Forensic Psychiatry and Psychology*, 2012; 23 (2): 200-16.

Not a study of qualitative design of experiences

Alia-Klein N, O'Rourke TM, Goldstein RZ, Malaspina D. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. *Aggressive Behavior*, 2007; 33 (1): 86-96.

Anderson PD. Forensic aspects of drug interactions, part I. *The Forensic Examiner*, 1999; 8 (9): 14-17.

Canvin K, Bartlett A, Pinfold V. A 'bittersweet pill to swallow': learning from mental health service users' responses to compulsory community care in England. *Health & Social Care in the Community*, 2002; 10 (5): 361-69.

Chester V, Henriksen M. Pain experience and management in a forensic intellectual disability service. *Advances in Mental Health and Intellectual Disabilities*, 2014; 8 (2): 120-27.

Coffey M. A risk worth taking? Value differences and alternative risk constructions in accounts given by patients and their community workers following conditional discharge from forensic mental health services. *Health, Risk & Society*, 2012; 14 (5): 465-82.

Cuddeback GS, Pettus-Davis C, Scheyett A. Consumers' perceptions of forensic assertive community treatment. *Psychiatric rehabilitation journal*, 2011; 35 (2): 101-09.

Dornan J, Kennedy M, Garland J, Rutledge E, Kennedy HG. Functional mental capacity, treatment as usual and time: magnitude of change in secure hospital patients with major mental illness. *BMC Research Notes*, 2015; 8566.

Haw C, Stubbs J, Bickle A, Stewart I. Coercive treatments in forensic psychiatry: A study of patients' experiences and preferences. *Journal of Forensic Psychiatry and Psychology*, 2011; 22 (4): 564-85.

Isherwood T, Burns M, Rigby G. A qualitative analysis of the 'management of schizophrenia' within a medium-secure service for men with learning disabilities. *Journal of Psychiatric and Mental Health Nursing*, 2006; 13 (2): 148-56.

Kamphuis J, Karsten J, de Weerd A, Lancel M. Sleep disturbances in a clinical forensic psychiatric population. *Sleep Medicine*, 2013; 14 (11): 1164-9.

Loubser I, Chaplin R, Quirk A. Violence, alcohol and drugs: The views of nurses and patients on psychiatric intensive care units, acute adult wards and forensic wards. *Journal of Psychiatric Intensive Care*, 2009; 5 (1): 33-39.

Maidment ID, Brown P, Calnan M. An exploratory study of the role of trust in medication management within mental health services. *International Journal of Clinical Pharmacy*, 2011; 33 (4): 614-20.

Maier GJ. The impact of clozapine on 25 forensic patients. *Bulletin of the American Academy of Psychiatry & the Law*, 1992; 20 (3): 297-307.

McGauley G. The actor, the act and the environment: Forensic psychotherapy and risk. *International Review of Psychiatry*, 1997; 9 (2): 257-64.

McLaren S, Browne FW, Taylor PJ. A study of psychotropic medication given 'as required' in a regional secure unit. *British Journal of Psychiatry*, 1990; 156:732-5.

Meehan T, McIntosh W, Bergen H. Aggressive behaviour in the high-secure forensic setting: the perceptions of patients. *Journal of psychiatric and mental health nursing*, 2006; 13 (1): 19-25.

Mezey GC, Kavuma M, Turton P, Demetriou A, Wright C. Perceptions, experiences and meanings of recovery in forensic psychiatric patients. *Journal of Forensic Psychiatry and Psychology*, 2010; 21 (5): 683-96.

Mohr P, Knytl P, Voráčková V, Bravermanová A, Melicher T, Voráčková V, et al. Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients. *International Journal of Clinical Practice*, 2017; 71 (9): n/a-n/a.

Mortlock A-M, Larkin F, Ross CC, Gupta N, Sengupta S, Das M. Effectiveness of paliperidone depot injection in seriously violent men with comorbid schizophrenia and dissocial personality disorder in a UK high-security hospital. *Therapeutic advances in psychopharmacology*, 2017; 7 (5): 169-79.

Pulsford D, Crumpton A, Baker A, Wilkins T, Wright K, Duxbury J. Aggression in a high secure hospital: Staff and patient attitudes. *Journal of Psychiatric and Mental Health Nursing*, 2013; 20 (4): 296-304.B340

Qurashi I, Stephenson P, Chu S, Duffy C, Husain N, Chaudhry I. An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service. *Therapeutic Advances in Psychopharmacology*, 2015; 5 (3): 146-50.

Repo-Tiihonen E, Vuorio O, Koivisto H, Paavola P, Hakola P. Opinions About Treatment Modalities Among Patients Involuntarily Committed to a Forensic Psychiatric Hospital in Finland. *Journal of Offender Rehabilitation*, 2004; 38 (3): 81-95.

Riordan S, Humphreys M. Patient perceptions of medium secure care. *Medicine, Science and the Law*, 2007; 47 (1): 20-26.

Swinton M, McNamee H. Clozapine in forensic settings: persuading patients. *The British Journal of Forensic Practice*, 2003; 5 (2): 33-38.

Vartiainen H, Vuorio O, Halonen P, Hakola P. The patients' opinions about curative factors in involuntary treatment. *Acta Psychiatrica Scandinavica*, 1995; 91 (3): 163-66.

Wright KM, Duxbury JA, Baker A, Crumpton A. A qualitative study into the attitudes of patients and staff towards violence and aggression in a high security hospital. *Journal of Psychiatric and Mental Health Nursing*, 2014; 21 (2): 184-88.

Not a primary study

Ahmed M, Bursztajn HJ, Abramson RD. Back to the future. *Psychiatric Services*, 2016; 67 (5): 473-73.

Bressington D, Gray R, Lathlean J, Mills A. Antipsychotic medication in prisons: satisfaction with and adherence to treatment. *Mental Health Practice*, 2008; 11 (10): 18-21.

Cintron DL. A qualitative case study of incarceration for mentally ill individuals in Southwest Florida. Vol. 77, ProQuest Information & Learning, US DB - psych DP - EBSCOhost, 2016.

Ehret MJ, Shelton D. Psychotropic medication adherence: Development of an inmate interview process. *Journal of Pharmacy Practice*, 2011; 24 (2): 277.

Haddad PM, Chaudhry IB, Husain N, McLaughlin S, Cunningham P, David AS, et al. Psychiatrists' attitudes to antipsychotic depot injections (N=102): Preferences and choice. *European Neuropsychopharmacology*, 2008; 18S415-S16.

Ho DK, Kottalgi G, Ross CC, Romero-Ulceray J, Das M. Treatment with triptorelin in mentally disordered sex offenders: experience from a maximum-security hospital. *Journal of Clinical Psychopharmacology*, 2012; 32 (5): 739-40.

Schindler VP. The development of roles and role skills in adults diagnosed with schizophrenic disorders in a forensic setting. Vol. 63, ProQuest Information & Learning, US DB - psych DP - EBSCOhost, 2002, pp. 1573-73.

Simpson AIF, Penney SR. The recovery paradigm in forensic mental health services. *Criminal Behaviour and Mental Health*, 2011; 21 (5): 299-306.

Spitz RT. Treatment noncompliance among hospitalized forensic patients. Vol. 60, ProQuest Information & Learning, US DB - psych DP - EBSCOhost, 1999, pp. 0815-15.

Stewart D, Anthony GB, Chesson R. 'It's not my job. I'm the patient not the doctor': Patient perspectives of medicines management in the treatment of schizophrenia. *International Journal of Pharmacy Practice*, 2010; 1844.

Talina M, Cardoso A, Aguiar P, Caldas De Almeida J, Xavier M. How different are the needs for care between forensic and civil psychiatric services users? *European Psychiatry*, 2012; 27.

Language

Prunnlechner-Neumann R, Miller C. Forensic-psychiatric drug-therapy. *Neuropsychiatrie*, 2005; 19 (3): 89-96.

Runte-Geidel A, Girela E, López A, Ruiz F, Torres-González F. Study of coercive measures in prisons and secure psychiatric hospitals: the views of inmates and caregivers. *Revista española de sanidad penitenciaria*, 2014; 16 (1): 3-10.

Health economics

wrong PICO

Adi Y, Ashcroft D, Browne K, Beech A, Fry-Smith A, Hyde C. Clinical effectiveness and cost consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders 2002. 1-66 p.

Barrett B, Byford S, Seivewright H, Cooper S, Duggan C, Tyrer P. The assessment of dangerous and severe personality disorder: service use, cost, and consequences. *Journal of Forensic Psychiatry and Psychology*. 2009;20(1):120-31.

Brown D, Larkin F, Sengupta S, Romero-Ureclay JL, Ross CC, Gupta N, et al. Clozapine: An effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. *CNS Spectrums*. 2013;19(5):391-402.

Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. *Acta Psychiatrica Scandinavica*. 2007;116(1):36-46.

Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K. Value for money in drug treatment: economic evaluation of prison methadone (Structured abstract). *Drug and Alcohol Dependence [Internet]*. 2006; 84(2):160-6 pp.

Zarkin GA, Cowell AJ, Hicks KA, Mills MJ, Belenko S, Dunlap LJ, et al. Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model. *Health Economics*. 2012;21(6):633-52.

Zhu B, Ascher-Svanum H, Faries DE, Peng X, Salkever D, Slade EP. Costs of treating patients with schizophrenia who have illness-related crisis events. *BMC Psychiatry*. 2008;8:72.

Not an economic review

Fontanarosa J, Uhl S, Oyesanmi O, Schoelles KM. Interventions for adult offenders with serious mental illness. 2013:i-76.

Keltner NL, Vance DE. Biological perspectives: Incarcerated care and quetiapine abuse. *Perspectives in Psychiatric Care*. 2008;44(3):202-6.

Maier GJ, Miller RD, Roach L. The real cost of clozapine: a patient buys freedom. *Hosp Community Psychiatry*. 1992;43(2):177-8.

Mattes JA. Medications for aggressiveness in prison: focus on oxcarbazepine. *J Am Acad Psychiatry Law*. 2012;40(2):234-8.

Morris PJ. Compliance profile of Depakote ER compared to Depakote DR and valproic acid in bipolar patients. *J*. 2008;14(4):311-7.

Pinals DA, Buckley PF. Novel antipsychotic agents and their implications for forensic psychiatry. *J Am Acad Psychiatry Law*. 1999;27(1):7-22.

Duplicate

Zarkin GA, Dunlap LJKA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model (Structured abstract). *Health Economics [Internet]*. 2005; 14(2):1133-50 pp.

Too low quality

Lin I, Muser E, Munsell M, Benson C, Menzin J. Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis. *Journal of Medical Economics*, 2015; 18 (3): 219-29.

Muser E, Kozma CM, Benson CJ, Mao L, Starr HL, Alphs L, et al. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement. *Journal of Medical Economics*, 2015; 18 (8): 637-45.

Antimanic agents

Wrong population

Cueva EJ, John E, Small AM, Armenteros, JI, Perry R, Campbell M. Carbamazepine in Aggressive Children with Conduct Disorder: A Double-Blind and Placebo-Controlled Study. *J Am Acad Child Adolesc Psychiatry*. 1996. Apr;35(4):480-90.

Donovan SJ, Stewart JW, Nunes EV, Quitkin FM, Parides M, Daniel W, Susser E, Klein DF. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. *Am J Psychiatry*. 2000 May;157(5):818-20.

Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarccone JR, Reese RM, Hall S, Ermer DJ, Tsai LY, Schroeder SR, Cook EH. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. *J Child Adolesc Psychopharmacol*. 2005 Aug;15(4):682-92.

Stanford MS, Helfritz LE, Conklin SM, Villemarette-Pittman NR, Greve KW, Adams D, Houston RJ. A comparison of anticonvulsants in the treatment of impulsive aggression. *Exp Clin Psychopharmacol*. 2005 Feb;13(1):72-7.

Zarghami M, Sheikhmoonesi F, Ala S, Yazdani J, Farnia S. A comparative study of beneficial effects of Olanzapine and sodium valproate on aggressive behavior of patients who are on methadone maintenance therapy: a randomized triple blind clinical trial. *Eur Rev Med Pharmacol Sci*. 2013 Apr;17(8):1073-81.

Intervention

Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of association with valproic acid P. Bozzatello¹ °, S. Bellino¹, F. Bogetto² ¹Centre for Personality Disorders Psychiatric Clinic 1, Department of Neuroscience University of Turin, Turin, Italy; ²Psychiatric Clinic 1, Department of Neuroscience University of Turin, Turin, Italy

Study design

Eatmon CV, Daniel JS. Should you use an anticonvulsant to treat impulsivity and aggression? *Current Psychiatry*, 2014; 13 (4): 49-51.

Joubert PM. Psychiatric uses of topiramate: What is the current evidence? *South African Journal of Psychiatry*, 2008; 14 (2): 44-50.

Pavlovic ZM. Lamotrigine for the treatment of impulsive aggression and affective symptoms in a patient with borderline personality disorder comorbid with body dysmorphic disorder. *J Neuropsychiatry Clin Neurosci*. 2008 Winter;20(1):121-2.

Pavlovic ZM. Augmentation of clozapine's antiaggressive properties with lamotrigine in a patient with chronic disorganized schizophrenia. *J Clin Psychopharmacol*. 2008 Feb;28(1):119-20

Ripoll LH, Triebwasser J, Siever LJ. Evidence-based pharmacotherapy for personality disorders. *Int J Neuropsychopharmacol*. 2011 Oct;14(9):1257-88.

Saunders EF, Silk KR. Personality trait dimensions and the pharmacological treatment of borderline personality disorder. *J Clin Psychopharmacol*. 2009 Oct;29(5):461-7.

Outcome

Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. *Neuropsychopharmacology*. 2003 Jun;28(6):1186-97.

Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, Nickel MK. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. *J Psychopharmacol*. 2005 May;19(3):287-91.

Leiberich P, Nickel MK, Tritt K, Pedrosa Gil F. Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up. *J Psychopharmacol*. 2008 Sep;22(7):805-8.

Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, Rother WK, Loew TH. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. *J Clin Psychiatry*. 2004 Nov;65(11):1515-9.

Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, Krawczyk J, Leiberich PK, Rother WK, Loew TH. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. *Biol Psychiatry*. 2005 Mar 1;57(5):495-9.

Nickel MK, Loew TH. Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. *Eur Psychiatry*. 2008 Mar;23(2):115-7.

Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. *Am J Psychiatry*. 1986 Apr;143(4):519-22.

Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. *Int Clin Psychopharmacol*. 2009 Sep;24(5):270-5.

Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, Fartacek R, Lahmann C, Buschmann W, Tritt K, Bachler E, Mitterlehner F, Pedrosa Gil F, Leiberich P, Rother WK, Egger C. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. *J Clin Psychopharmacol*. 2006 Feb;26(1):61-6.

Nickel M, Loew T. Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. *European psychiatry*, 2008; 23 (2): 115-17.

Bellino S, Bozzatello P, Brunetti C, Grandi E, Bogetto F. Omega-3 fatty acids associated with valproate in the treatment of borderline personality disorder: a controlled study. *Journal of psychopathology*, 2013; 19 (4): 296-303.

Bellino S, Bozzatello P, Rocca G, Bogetto F. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. *J Psychopharmacol*. 2014 Feb;28(2):125-32.

Bozzatello P, Rocca P, Bellino S. Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study. *Clin Drug Investig*. 2018 Apr;38(4):367-372.

Mood stabilisers in the treatment of personality disorders and comorbid depression M. Todorovic¹ °, I. Perunicic¹, I. Rakovic¹ ¹Institute of mental health, Clinical Ward, Belgrade, Serbia